A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice

文献类型： 外文期刊

第一作者： Wang, Zhenfei

作者： Wang, Zhenfei;Sun, Weiyang;Li, Dongxu;Sun, Yue;Zhu, Menghan;Wang, Wenqi;Zhang, Yiming;Li, Entao;Yan, Feihu;Wang, Tiecheng;Feng, Na;Yang, Songtao;Xia, Xianzhu;Gao, Yuwei;Wang, Zhenfei;Li, Dongxu;Sun, Yue;Zhu, Menghan;Wang, Wenqi;Zhang, Yiming

作者机构：

关键词： SARS-CoV-2; Influenza virus -vector vaccine; Spike RBD; Intranasal vaccination; Mice

期刊名称：VIRUS RESEARCH （ 影响因子：5.0； 五年影响因子：4.0 ）

ISSN： 0168-1702

年卷期： 2024 年 345 卷

页码：

收录情况： SCI

摘要： Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to human health globally. It is crucial to develop a vaccine to reduce the effect of the virus on public health, economy, and society and regulate the transmission of SARS-CoV-2. Influenza B virus (IBV) can be used as a vector that does not rely on the current circulating influenza A strains. In this study, we constructed an IBV-based vector vaccine by inserting a receptor -binding domain (RBD) into a non-structural protein 1 (NS1)-truncated gene (rIBV-NS110-RBD). Subsequently, we assessed its safety, immunogenicity, and protective efficacy against SARS-CoV-2 in mice, and observed that it was safe in a mouse model. Intranasal administration of a recombinant rIBV-NS110-RBD vaccine induced high levels of SARS-CoV-2-specific IgA and IgG antibodies and T cell -mediated immunity in mice. Administering two doses of the intranasal rIBV-NS110-RBD vaccine significantly reduced the viral load and lung damage in mice. This novel IBV-based vaccine offers a novel approach for controlling the SARS-CoV-2 pandemic.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序